Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry

Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry

Most patients with glioblastoma (GBM) die within 2 years. A major therapeutic goal is to target GBM stem cells (GSCs), a subpopulation of cells that contribute to treatment resistance and recurrence. Since their discovery in 2003, GSCs have been isolated using single-surface markers, such as CD15, C...

Full description

Bibliographic Details
Main Authors: Luciano Galdieri, Arijita Jash, Olga Malkova, Diane D. Mao, Patrick DeSouza, Yunli E. Chu, Amber Salter, Jian L. Campian, Kristen M. Naegle, Cameron W. Brennan, Hiroaki Wakimoto, Stephen T. Oh, Albert H. Kim, Milan G. Chheda
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-02-01
Series:JCI Insight
Subjects:
Oncology
Online Access:https://doi.org/10.1172/jci.insight.128456

Internet

https://doi.org/10.1172/jci.insight.128456

Similar Items